Liraglutida: La liraglutida, tambin desarrollada por Novo Nordisk, fue uno de los primeros agonistas GLP-1 aprobados para diabetes tipo 2 y, ms tarde, para el tratamiento de la obesidad
A marked expansion in the exocrine and endocrine compartments of the pancreas with an increase in pancreatic mass augmented exocrine cell proliferation, and dysplasia was reported in diabetic patients on incretin mimetic therapy [75]
Semaglutide has emerged as a powerful tool for weight loss, helping individuals manage their appetite and cravings
The majority of SSIB cases reported in the current RCT and post-marketing study are not considered to be related to GLP-1 RAs
This product is sold strictly for laboratory research purposes only
[DOI] [PubMed] [Google Scholar] 70.Fede G, Germani G, Gluud C, Gurusamy KS, Burroughs AK